Efficacy analysis of enteral nutrition combined with biological agents in adult Crohn's disease

Yang Wenjun; Li Xiyou; Liang Shiwei; Yao Li

doi:10.3760/j.issn.1673-4777.2025.06.012

Abstract：Objective To investigate the efficacy and safety of enteral nutrition combined with biological agents(infliximab or ustekinumab)in the induction of remission in adults with moderate to severe Crohn's disease.Methods The clinical data of Crohn's disease patients diagnosed in the Second Affiliated Hospital of Guilin Medical College and the Second Affiliated Hospital of Guangxi Medical University from October 2018 to October 2024 were retrospectively selected.They were divided into observation group(14 cases)and control group(15 cases)according to whether they were combined with enteral nutrition.The observation group was treated with enteral nutrition and biological agents,and the control group was treated with less residue diet and biological agents.The general clinical data,laboratory indexes before and after treatment,body mass index and Crohn's disease activity index(CDAI)score were compared between the two groups to evaluate the disease activity,and the occurrence of adverse reactions was recorded.Results After treatment,the body mass index and albumin level of the two groups were higher than those before treatment,and those of the observation group were higher than those of the control group[body mass index:(21.2±2.1)kg/m2 vs(19.3±2.9)kg/m2],and the erythrocyte sedimentation rate and CDAI of the two groups were lower than those before treatment,and those of the observation group were lower than those of the control group(all P＜0.05).All patients had a clinical response.There were 12 cases(85.7％)of clinical remission in the observation group and 11 cases(73.3％)in the control group(x2=0.132,P=0.716).During the treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Enteral nutrition combined with biological agents is beneficial to induce remission of moderate to severe Crohn's disease in adults with good safety.